STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Tozorakimab reduced COPD exacerbations by approximately 30% across all patients over a year in Phase 3 trials, according to data released Tuesday and simultaneously published in the New England Journal of Medicine and presented at the European Respiratory Society's annual conference in Barcelona.
- AstraZeneca could capture a large, relatively uncontested segment of the COPD market because the tozorakimab trials enrolled patients who were ineligible for other recently approved COPD drugs.
- Analysts and AstraZeneca project tozorakimab could reap billions in annual sales if approved, with additional potential applications beyond COPD including asthma.
- AstraZeneca had absorbed notable recent trial setbacks — most dramatically a heart-disease drug failure — making the tozorakimab results a re-assuring win for a company long known for metronomic trial success.
- COPD remains the third-leading cause of death globally and is greatly underserved by current treatments, reinforcing demand for new therapeutic options.
Why it matters: Tozorakimab's roughly 30% reduction in flare-ups — achieved in a trial population that included patients excluded from trials of newer competing drugs — could hand AstraZeneca a commercial foothold in the underserved COPD market, where analysts project billions in annual sales and where the company needed a win after its recent heart-drug setback.
Ask SkimNews
